Syntis Bio has dosed the first patient in the SYNTIETY-1 Phase I/Ib trial of SYNT-101, its investigational once-daily oral pill, targeting obesity.
The study aims to assess the therapy’s tolerability, safety, pharmacokinetics, and pharmacodynamics.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Underway in Australia, it includes healthy volunteers, overweight or obese patients. The 28-day multi-ascending dose portion will measure changes in metabolic biomarkers associated with weight management.
SYNT-101 is designed to temporarily block nutrient absorption in the duodenum, redirecting nutrients to the distal small intestine. This mechanism stimulates the release of satiety and metabolism-regulating hormones such as glucagon-like peptide-1 (GLP-1), reflecting the effect seen with gastric bypass surgery.
Syntis Bio’s CEO Rahul Dhanda said: “Dosing of our first SYNTIETY-1 patient is a significant milestone for Syntis and for the SYNT-101 clinical programme.
“This progress underscores the potential of our SYNT platform, which is designed to harness the biology of the small intestine to develop the next generation of oral therapeutics, either as monotherapy treatments or as co-formulations to enhance or combine the effects of other drugs.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition to this clinical update, Syntis Bio has appointed David Rosenbaum as chief development officer and Christo Shalish as chief business officer.
Rosenbaum said: “I am thrilled to join Syntis at this inflection point. The company’s mission and scientific approach have immense potential to help patients globally and across the healthcare spectrum.
“Launching the SYNT-101 clinical programme is a significant milestone that reflects our continued progress in advancing a differentiated obesity pipeline into the clinic. I look forward to helping guide clinical development for both SYNT-101 and future programmes that will combine the SYNT platform with additional therapies.”
